On March 9, 2026, the Institute of Public Health of Chile (ISP) published a resolution introducing guidance on regulatory reliance mechanisms for pharmaceutical inspections. The resolution, which became effective on January 28, 2026, establishes a framework allowing Chilean regulators to rely on inspection findings from trusted international authorities when assessing Good Manufacturing Practices (GMP) compliance.
The update applies to both domestic and imported pharmaceutical products and affects manufacturers, marketing authorization holders, and organizations involved in production, distribution, and storage. The goal is to strengthen oversight of pharmaceutical good practices while improving efficiency in inspection processes.
Details of the Update
Under the new guidance, the ISP introduces a structured reliance mechanism that allows inspection reports issued by recognized international authorities to support regulatory verification in Chile.
Inspection reports from agencies recognized by PAHO/WHO or the Pharmaceutical Inspection Co-operation Scheme (PIC/S) may be used by Chilean authorities to verify GMP compliance for foreign pharmaceutical manufacturers. These reports can support regulatory assessments related to manufacturing conditions and quality systems.
The guidance also introduces risk-based monitoring informed by findings from foreign regulatory inspections. These findings may influence regulatory decisions affecting imported pharmaceutical products and their registration holders, including compliance verification and oversight activities.
In addition, the mechanism supports the annual prioritization of foreign manufacturing plant inspections associated with pharmaceutical products entering the Chilean market. By using inspection outcomes from trusted international regulators, the ISP aims to allocate inspection resources more efficiently while maintaining quality assurance standards.
To support this framework, stakeholders must ensure that inspection documentation issued by recognized regulatory authorities is available for review when requested by the Chilean regulator. This documentation may be required during regulatory assessments or compliance checks.
Overall, the guidance promotes harmonized quality standards across domestic and international pharmaceutical suppliers operating under Chile’s regulatory oversight.
Effective Date
The resolution establishing regulatory reliance mechanisms for the Subdepartment of Inspections within the National Medicines Agency took effect on January 28, 2026.
Why It Matters
The introduction of regulatory reliance mechanisms supports regulatory harmonization and efficiency in pharmaceutical inspections. By recognizing inspection findings from trusted international regulators, the ISP can enhance risk-based monitoring, reduce duplicative inspection activities, and maintain oversight of GMP compliance for products entering the Chilean market while minimizing administrative burden.
Who This Is Relevant For
This update is relevant for pharmaceutical manufacturers, marketing authorization holders, regulatory affairs teams, quality assurance professionals, and supply chain stakeholders involved in the production, importation, distribution, and storage of medicinal products intended for the Chilean market.
Next Steps
Stakeholders should evaluate current inspection preparedness and internal compliance procedures to ensure alignment with the newly established reliance mechanisms. Organizations should also verify that inspection reports and supporting documentation from recognized international authorities are readily available for regulatory review if requested.
Companies are encouraged to review the full resolution issued by the Institute of Public Health of Chile (ISP) to understand the detailed expectations related to documentation and inspection oversight.
As regulatory authorities increasingly adopt reliance mechanisms and international cooperation frameworks, maintaining visibility into inspection outcomes and cross-border compliance requirements becomes critical for global pharmaceutical operations.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What regulatory change did Chile’s ISP introduce for pharmaceutical inspections?
The Institute of Public Health of Chile (ISP) introduced guidance establishing regulatory reliance mechanisms, allowing Chilean authorities to use inspection findings from recognized international regulators to support oversight of Good Manufacturing Practices (GMP).
Which international inspection authorities are recognized under the guidance?
Inspection reports from agencies listed by PAHO/WHO or members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) may be used to support GMP compliance verification for foreign pharmaceutical manufacturers.
Who is affected by the new regulatory reliance framework in Chile?
The guidance affects pharmaceutical manufacturers, marketing authorization holders, and organizations involved in the production, distribution, and storage of medicinal products supplied to the Chilean market.
How can RegASK help companies adapt to evolving inspection and regulatory reliance frameworks?
RegASK helps organizations monitor global regulatory updates, inspection frameworks, and compliance requirements across multiple jurisdictions. Through AI-driven regulatory intelligence and workflow automation, the platform supports regulatory and quality teams in staying aligned with evolving oversight mechanisms such as regulatory reliance initiatives.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
